AUPH · Insider Trading
Aurinia Pharmaceuticals Inc
Every open-market purchase and sale reported by AUPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Stephen P. Robertson | Chief Legal Officer | Sell | −11,939 | −$190.43K |
| 2026-08-25 | Stephen P. Robertson | Chief Legal Officer | Sell | −20,975 | −$355.95K |
| 2026-06-08 | Jeffrey Allen Bailey | Director | A | +23,931 deriv. | — |
| 2026-06-08 | Tina Susan Nova | Director | A | +23,931 deriv. | — |
| 2026-06-08 | Craig A Johnson | Director | A | +23,931 deriv. | — |
| 2026-06-08 | Kathleen Goetz | Director | A | +23,931 deriv. | — |
| 2026-06-02 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy | +1,629,212 | +$24.91M |
| 2026-05-20 | Stephen P. Robertson | Chief Legal Officer | A | +115,541 | — |
| 2026-05-20 | Michael S Hearne | Chief Financial Officer | A | +116,144 | — |
| 2026-05-20 | Ryan Cole | Chief Operating Officer | A | +116,144 | — |
| 2026-03-10 | Greg Keenan | SVP, Chief Medical Officer | F | −8,069 | −$115.55K |
| 2026-03-03 | Peter Greenleaf | Chief Executive Officer | MIXED | +95,513 | −$1.43M |
| 2026-03-03 | Stephen P. Robertson | EVP, General Counsel | MIXED | +22,565 | −$519.02K |
| 2026-03-03 | Joseph M Miller | Chief Financial Officer | MIXED | +19,718 | −$533.03K |
| 2026-03-03 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | +17,399 | −$579.21K |
| 2026-03-03 | Greg Keenan | SVP, Chief Medical Officer | A | +40,586 | — |
| 2026-03-03 | Kevin Tang | Director | Buy | +900,000 | +$12.69M |
| 2026-02-23 | Stephen P. Robertson | EVP, General Counsel | F | −34,638 | −$498.79K |
| 2026-02-23 | Matthew Maxwell Donley | Chief Operating Officer | F | −32,901 | −$473.77K |
| 2026-02-23 | Peter Greenleaf | Chief Executive Officer | F | −100,171 | −$1.44M |
| 2026-02-23 | Joseph M Miller | Chief Financial Officer | F | −32,424 | −$466.91K |
| 2026-02-03 | Greg Keenan | SVP, Chief Medical Officer | F | −11,552 | −$167.85K |
| 2026-01-05 | Stephen P. Robertson | EVP, General Counsel | MIXED | +8,173 | −$644.14K |
| 2026-01-05 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | +11,379 | −$682.45K |
| 2026-01-05 | Joseph M Miller | Chief Financial Officer | MIXED | +8,877 | −$640.57K |
| 2026-01-05 | Peter Greenleaf | Chief Executive Officer | MIXED | +52,215 | −$1.81M |
| 2025-11-24 | Jeffrey Allen Bailey | Director | F | −2,716 | −$42.59K |
| 2025-11-24 | Craig A Johnson | Director | F | −6,039 | −$94.69K |
| 2025-08-05 | Greg Keenan | Chief Medical Officer | Sell | −20,000 | −$210.00K |
| 2025-08-05 | Kevin Tang | Director | Buy | +1,300,000 | +$13.59M |
| 2025-05-16 | Craig A Johnson | Director | A | +37,485 deriv. | — |
| 2025-05-16 | Kathleen Goetz | Director | A | +63,724 deriv. | — |
| 2025-05-16 | Jeffrey Allen Bailey | Director | A | +37,485 deriv. | — |
| 2025-05-16 | Tina Susan Nova | Director | A | +63,724 deriv. | — |
| 2025-03-07 | Greg Keenan | Chief Medical Officer | Sell | −8,305 | −$68.35K |
| 2025-03-04 | Matthew Maxwell Donley | Chief Operating Officer | MIXED | +93,455 | −$994.42K |
| 2025-03-04 | Joseph M Miller | Chief Financial Officer | MIXED | +78,155 | −$939.61K |
| 2025-03-04 | Stephen P. Robertson | EVP, General Counsel | MIXED | +64,033 | −$975.22K |
| 2025-03-04 | Greg Keenan | Chief Medical Officer | MIXED | +50,344 | −$97.91K |
| 2025-03-04 | Peter Greenleaf | Chief Executive Officer | MIXED | +263,893 | −$2.87M |
| 2025-03-04 | Kevin Tang | Director | Buy | +1,600,000 | +$12.71M |
| 2024-12-09 | Kevin Tang | Director | Buy | +1,200,000 | +$10.82M |
| 2024-11-25 | David R.W. Jayne | Director | A | +12,135 | — |
| 2024-11-25 | Jill Leversage | Director | A | +12,135 | — |
| 2024-11-25 | Karen L. Smith | Director | A | +12,135 | — |
| 2024-11-25 | Jeffrey Allen Bailey | Director | A | +12,135 | — |
| 2024-11-25 | Craig A Johnson | Director | A | +20,631 | — |
| 2024-11-12 | Jeffrey Allen Bailey | Director | MIXED | +13,356 | −$38.42K |
| 2024-11-12 | Karen L. Smith | Director | MIXED | +12,672 | −$44.18K |
| 2024-08-08 | Scott Michael Habig | Chief Commercial Officer | Sell | −18,249 | −$96.90K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | 12,838,002 | $218.89M |
| Kevin Tang | Director | 12,229,500 | $208.51M |
| Peter Greenleaf | Chief Executive Officer | 1,941,269 | $33.10M |
| Matthew Maxwell Donley | Chief Operating Officer | 680,299 | $11.60M |
| Joseph M Miller | Chief Financial Officer | 613,932 | $10.47M |
| Stephen P. Robertson | Chief Legal Officer | 588,848 | $10.04M |
| Greg Keenan | SVP, Chief Medical Officer | 154,449 | $2.63M |
| Michael S Hearne | Chief Financial Officer | 116,144 | $1.98M |
| Ryan Cole | Chief Operating Officer | 116,144 | $1.98M |
| David R.W. Jayne | Director | 56,499 | $963.31K |
| Jill Leversage | Director | 26,053 | $444.20K |
| Karen L. Smith | Director | 24,807 | $422.96K |
| Jeffrey Allen Bailey | Director | 22,775 | $388.31K |
| Craig A Johnson | Director | 14,592 | $248.79K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AUPH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.